Intensive capital, long development times, endless and costly trial processes in the different phases and very high chances of failure. This is the ordeal that awaits any young company that strives to investigate the launch of a new drug.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.
Intensive capital, long development times, endless and costly trial processes in the different phases and very high chances of failure. This is the ordeal that awaits any young company that strives to investigate the launch of a new drug.